

## Annual General Meeting Results

Melbourne, Australia, November 29, 2022 – Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') is pleased to attach the results of the Annual General Meeting held on 29 November 2022 as set out in the attached document.

All the resolutions were passed and decided by way of a poll.

The Board of Directors has authorised this announcement to be given to ASX.

ENDS:

For Further Information, contact:

Madhukar Bhalla

Company Secretary

T: +61 (0) 417 935 552

E: [madhu@incannex.com.au](mailto:madhu@incannex.com.au)

**END**



Date: November 29, 2022  
Public Announcement (NASDAQ: IXHL) (ASX: IHL)

### **About Incannex Healthcare Limited**

Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.

U.S. FDA approval and registration, subject to ongoing clinical success, is being pursued for each drug and therapy under development. Each indication under investigation currently has no, or limited, existing registered pharmacotherapy (drug) treatments available to the public and represent major global economic opportunities to Incannex and its shareholders.

Incannex has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. The Company holds 19 granted patents and 30 pending patents. Incannex is listed on the Australian Stock Exchange (ASX) with stock code "IHL" and has American Depository Shares listed on NASDAQ under code "IXHL".

**Website:** [www.incannex.com.au](http://www.incannex.com.au)

**Investors:** [investors@incannex.com.au](mailto:investors@incannex.com.au)

### **Forward-looking statements**

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations and estimates, as well as the beliefs and assumptions of management. The forward-looking statements included in this press release represent Incannex's views as of the date of this press release. Incannex anticipates that subsequent events and developments may cause its views to change. Incannex undertakes no intention or obligation to update or revise any forward-looking statements, whether as of a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Incannex's views as of any date after the date of this press release.

### **Contact Information:**

#### **Incannex Healthcare Limited**

Mr Joel Latham  
Managing Director and Chief Executive Officer  
+61 409 840 786  
[joel@incannex.com.au](mailto:joel@incannex.com.au)

#### **Investor Relations Contact – United States**

Alyssa Factor  
Edison Group  
+1 (860) 573 9637  
[afactor@edisongroup.com](mailto:afactor@edisongroup.com)

# Disclosure of Proxy Votes

## INCANNEX HEALTHCARE LIMITED

Annual General Meeting

Tuesday, 29 November 2022



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Remuneration Report	P	555,198,711	510,023,795 91.86%	43,726,160 7.88%	198,373	1,448,756 0.26%	525,856,569 92.32%	43,726,160 7.68%	198,373
2 Re-election of Mr Troy Valentine as Director	P	628,862,472	511,422,371 81.32%	116,047,774 18.45%	107,918	1,392,327 0.22%	527,198,716 81.96%	116,047,774 18.04%	107,918
3 Election of Dr George Ansatassov as Director	P	628,070,365	559,941,366 89.15%	66,736,672 10.63%	900,025	1,392,327 0.22%	575,717,711 89.61%	66,736,672 10.39%	900,025
4 Election of Mr Robert Clark as Director	P	628,823,343	626,954,239 99.70%	476,777 0.08%	147,047	1,392,327 0.22%	642,730,584 99.93%	476,777 0.07%	147,047
5 Amendment to Constitution	P	628,647,938	533,721,806 84.90%	93,544,113 14.88%	322,452	1,382,019 0.22%	549,487,843 85.45%	93,544,113 14.55%	322,452
6 Approval to issue Options and Company Acquisition Incentive to Mr. Robert Clark, Director, as part of his remuneration package	P	628,584,914	595,512,826 94.74%	31,732,764 5.05%	385,476	1,339,324 0.21%	611,236,168 95.06%	31,732,764 4.94%	385,476
7 Appointment of Auditor	P	521,461,832	521,225,705 99.95%	42,864 0.01%	306,813	193,263 0.04%	535,802,986 99.99%	42,864 0.01%	306,813

